General Archive

-
LifeArc scientists play pivotal role in the search for a COVID-19 antibody therapy
While much attention in the race for treatments for Covid-19 has been on the development of new vaccines, scientists have…
-
Virtual reality technology for small molecular drug discovery
A project by an industrial placement student led to Virtual Reality becoming a powerful tool for drug discovery Technology has…
-
Life, re-engineered: new milestone in the emerging field of synthetic genomics
When MRC researchers achieved a new milestone in the emerging field of synthetic genomics, LifeArc set this early-stage technology on…
-
Modelling the human brain
Candidate drugs to treat the central nervous system could be screened with three-dimensional brain tissue grown in the laboratory. We…
-
Keytruda: a new generation of cancer treatment
In 2007, LifeArc entered a collaboration with Organon – ultimately acquired by Merck – to translate innovative drug targets into…
-
Cancer: LifeArc is working in partnership with Worldwide Cancer Research
We have worked in partnership with Worldwide Cancer Research (WCR) since 2011 to ensure that intellectual property arising from their…
-
Breast cancer: new treatment monitoring test avoids risks from biopsy
Through their shared dedication to patients, LifeArc and diagnostics company Biocartis are developing a ‘liquid biopsy’ test for breast cancer…
-
Renishaw Diagnostics: a test for antibiotic resistance
We collaborated with Renishaw Diagnostics Ltd. on a rapid diagnostic test for the detection of carbapenemase genes, which are associated…
-
News releases
TYSABRI gains market approval
Biogen Idec and Elan Corporation yesterday announced the approval of a supplemental Biologics License Application (sBLA) by the U.S. Food…
-
News releases
Therapeutic Antibody Group starts
The Therapeutic Antibody Group (TAG) will comprise former AERES scientists. As part of MRCT’s evolving strategy of adding significant value…